- Home
- SEAT vs AUTL Comparison
SEAT vs AUTL Comparison
Compare SEAT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEAT | AUTL |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.9M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SEAT | AUTL |
|---|---|---|
| Price | $7.24 | $1.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $32.94 | $8.67 |
| AVG Volume (30 Days) | 142.2K | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $643,775,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $669.49 |
| Revenue Next Year | N/A | $91.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $6.15 | $1.11 |
| 52 Week High | $100.00 | $2.70 |
Technical Indicators
Market Signals| Indicator | SEAT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 61.26 |
| Support Level | $6.21 | $1.77 |
| Resistance Level | $7.79 | $2.07 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 61.77 | 67.96 |
Price Performance
Historical ComparisonAbout SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.